» Articles » PMID: 33451133

A Closer Look at Estrogen Receptor Mutations in Breast Cancer and Their Implications for Estrogen and Antiestrogen Responses

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 16
PMID 33451133
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer (BC) is the most common cancer among women worldwide. More than 70% of BC cases express estrogen receptor alpha (ERα), a central transcription factor that stimulates the proliferation of breast cancer cells, usually in the presence of estrogen. While most cases of ER-positive BC initially respond to antiestrogen therapies, a high percentage of cases develop resistance to treatment over time. The recent discovery of mutated forms of ERα that result in constitutively active forms of the receptor in the metastatic-resistance stage of BC has provided a strong rationale for the development of new antiestrogens. These molecules targeting clinically relevant ERα mutants and a combination with other pharmacological inhibitors of specific pathways may constitute alternative treatments to improve clinical practice in the fight against metastatic-resistant ER-positive BC. In this review, we summarize the latest advances regarding the particular involvement of point mutations of ERα in endocrine resistance. We also discuss the involvement of synonymous ERα mutations with respect to co-translational folding of the receptor and ribosome biogenesis in breast carcinogenesis.

Citing Articles

In Silico Design of Dual Estrogen Receptor and Hsp90 Inhibitors for ER-Positive Breast Cancer Through a Mixed Ligand/Structure-Based Approach.

La Monica G, Alamia F, Bono A, Mingoia F, Martorana A, Lauria A Molecules. 2025; 29(24.

PMID: 39770128 PMC: 11676166. DOI: 10.3390/molecules29246040.


Investigation of the relationship between breast cancer and clinical symptoms of polycystic ovarian syndrome: a case-control study.

Hemati A, Amini L, Haghani S, Hashemi E BMC Womens Health. 2024; 24(1):586.

PMID: 39488687 PMC: 11531183. DOI: 10.1186/s12905-024-03421-4.


Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.

Hancock G, Gertz J, Jeselsohn R, Fanning S Endocrinology. 2024; 165(6).

PMID: 38643482 PMC: 11075793. DOI: 10.1210/endocr/bqae051.


Rapid differentiation of estrogen receptor status in patient biopsy breast cancer aspirates with an optical nanosensor.

Gaikwad P, Rahman N, Ghosh P, Ng D, Williams R bioRxiv. 2024; .

PMID: 38617252 PMC: 11014485. DOI: 10.1101/2024.03.29.587397.


Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.

Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S Signal Transduct Target Ther. 2024; 9(1):83.

PMID: 38570490 PMC: 10991592. DOI: 10.1038/s41392-024-01779-3.


References
1.
Barone I, Brusco L, Fuqua S . Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010; 16(10):2702-8. PMC: 4477803. DOI: 10.1158/1078-0432.CCR-09-1753. View

2.
Conway K, Parrish E, Edmiston S, Tolbert D, Tse C, Geradts J . The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study. Breast Cancer Res. 2005; 7(6):R871-80. PMC: 1410768. DOI: 10.1186/bcr1315. View

3.
Herynk M, Fuqua S . Estrogen receptor mutations in human disease. Endocr Rev. 2004; 25(6):869-98. DOI: 10.1210/er.2003-0010. View

4.
Maximov P, Lee T, Jordan V . The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2012; 8(2):135-55. PMC: 3624793. DOI: 10.2174/1574884711308020006. View

5.
Turner N, Kingston B, Kilburn L, Kernaghan S, Wardley A, Macpherson I . Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial. Lancet Oncol. 2020; 21(10):1296-1308. PMC: 7599319. DOI: 10.1016/S1470-2045(20)30444-7. View